Skip to main content

Tazemetostat for Relapsed/Refractory AML

Tazemetostat and Palbociclib With CPX-351for R/R AML

  • RegistryNCT05627232
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRelapsed or Refractory Acute Myeloid Leukemia
  • SponsorThomas Jefferson University
How Tazemetostat worksNCT056272321 min

What the film says

Read the transcript

This trial is for adults with acute myeloid leukemia that has come back or has not responded to prior treatment.

The idea: test two approaches with CPX-351, a liposomal chemotherapy given by vein. One part adds tazemetostat, a pill. The other pretreats with palbociclib before CPX-351. Both parts look for a safe dose to study further.

This phase 1 study plans 24 patients. At Thomas Jefferson University in Philadelphia, Gina Keiffer leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05627232

    Adults; relapsed/refractory AML; CPX-351 liposomal chemo by vein; part adds tazemetostat pill; part pretreats with palbociclib; Looks for safe dose for further evaluation; Phase 1; 24 patients (+1 more lines)

The drug

What is being tested.

PRIMARY OBJECTIVE: Part 1: To determine the RDFE of tazemetostat in combination with CPX-351 in patients with R/R-AML. Part 2: To determine the RDFE of palbociclib pre-treatment prior to CPX-351 in patients with R/R-AML. SECONDARY OBJECTIVE: I. To evaluate the preliminary efficacy of tazemetostat in combination with CPX-351 (Part 1) and of palbociclib pre-treatment followed by CPX-351 (Part 2). EXPLORATORY OBJECTIVES: 1.

To determine whether treatment with the EZH2 inhibitor tazemetostat de-condenses the H3K27me3-marked chromatin of AML blasts. 2.

The study

How the trial runs.

This is a two-part phase Ib dose escalation study to evaluate the safety and preliminary efficacy of the combination of tazemetostat and CPX-351 (Part 1) and of pre-treatment with palbociclib followed by CPX-351 (Part 2) for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).

Part 1 of the study will seek to establish the safety, tolerability, biological activity and recommended dose for further evaluation (RDFE) of tazemetostat in combination with standard-dose CPX-351. Part 2 of the study will seek to establish the safety, tolerability, biological activity RDFE of pre-treatment palbociclib prior CPX-351.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Provide signed and dated informed consent form
  • Willing to comply with all study procedures and be available for the duration of the study
  • Male or female >= 18 years of age
  • Histologically confirmed acute myeloid leukemia (non-M3) relapsed from or refractory to at least 1 prior line of therapy. Bone marrow aspirate and biopsy within 28 days of screening is acceptable. If no prior bone marrow biopsy is available, bone marrow biopsy must be performed during screening, unless the subject has >= 20% myeloblasts present in the peripheral blood, in which case a bone marrow biopsy is not necessary to meet this criterion
  • Treatment with a prior investigational agent is acceptable so long as it has not been administered within 2 weeks of enrollment and any prior adverse effects have resolved to grade 1 or less with the exception of alopecia

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.